{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:21:07Z","timestamp":1787610067185,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.1038\/s41388-026-03906-6","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:40:18Z","timestamp":1784889618000},"page":"3684-3701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-2299","authenticated-orcid":false,"given":"Ke-jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-9487","authenticated-orcid":false,"given":"Si-xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4356-165X","authenticated-orcid":false,"given":"Yong-bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-5902","authenticated-orcid":false,"given":"Sha-zhou","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2195-8304","authenticated-orcid":false,"given":"Jun-hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-6937","authenticated-orcid":false,"given":"Rui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-459X","authenticated-orcid":false,"given":"Ze-jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9822-7683","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-0362","authenticated-orcid":false,"given":"Qi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3906_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.eururo.2021.02.004","volume":"79","author":"S Gupta","year":"2021","unstructured":"Gupta S, Heemers HV. Treatment-induced treatment sensitization in metastatic castration-resistant prostate cancer. Eur Urol. 2021;79:734\u20135.","journal-title":"Eur Urol"},{"key":"3906_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrurol.2013.274","volume":"11","author":"L Yin","year":"2014","unstructured":"Yin L, Hu Q. CYP17 inhibitors\u2013abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 2014;11:32\u201342.","journal-title":"Nat Rev Urol"},{"key":"3906_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"3906_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"3906_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"3906_CR6","unstructured":"Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014;34. https:\/\/pubmed.ncbi.nlm.nih.gov\/25368223\/."},{"key":"3906_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.567809","volume":"10","author":"G Gurioli","year":"2020","unstructured":"Gurioli G, Conteduca V, Lolli C, Schepisi G, Gargiulo S, Altavilla A, et al. Plasma AR copy number changes and outcome to abiraterone and enzalutamide. Front Oncol. 2020;10:567809.","journal-title":"Front Oncol"},{"key":"3906_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"3906_CR9","unstructured":"Nuclear translocation of RON receptor tyrosine kinase. New mechanistic and functional insights - PubMed. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/39794156\/."},{"key":"3906_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrc3545","volume":"13","author":"H-P Yao","year":"2013","unstructured":"Yao H-P, Zhou Y-Q, Zhang R, Wang M-H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 2013;13:466\u201381.","journal-title":"Nat Rev Cancer"},{"key":"3906_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.canlet.2011.09.021","volume":"314","author":"JK Gray","year":"2012","unstructured":"Gray JK, Paluch AM, Stuart WD, Waltz SE. Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia. Cancer Lett. 2012;314:92\u2013101.","journal-title":"Cancer Lett"},{"key":"3906_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.neo.2018.07.003","volume":"20","author":"NE Brown","year":"2018","unstructured":"Brown NE, Paluch AM, Nashu MA, Komurov K, Waltz SE. Tumor cell autonomous RON receptor expression promotes prostate cancer growth under conditions of androgen deprivation. Neoplasia. 2018;20:917\u201329.","journal-title":"Neoplasia"},{"key":"3906_CR13","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/pros.24416","volume":"82","author":"NE Brown","year":"2022","unstructured":"Brown NE, Jones A, Hunt BG, Waltz SE. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. Prostate. 2022;82:1422\u201337.","journal-title":"Prostate"},{"key":"3906_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186871","volume":"10","author":"H Zhang","year":"2025","unstructured":"Zhang H, Kong L, Li J, Liu Z, Zhao Y, Lv X, et al. SPOP mutations increase PARP inhibitor sensitivity via CK2\/PIAS1\/SPOP axis in prostate cancer. JCI Insight. 2025;10:e186871.","journal-title":"JCI Insight"},{"key":"3906_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","volume":"8","author":"M Santoni","year":"2025","unstructured":"Santoni M, B\u00fcttner T, Rescigno P, Fiala O, Cavasin N, Basso U, et al. Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. Eur Urol Oncol. 2025;8:444\u201351.","journal-title":"Eur Urol Oncol"},{"key":"3906_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314\u201325.","journal-title":"N Engl J Med"},{"key":"3906_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34:477\u201385.","journal-title":"Ann Oncol"},{"key":"3906_CR18","first-page":"6547","volume":"15","author":"J-F Chen","year":"2018","unstructured":"Chen J-F, Yu B-X, Ma L, Lv X-Y, Jiang J-H, Ma Q. RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells. Oncol Lett. 2018;15:6547\u201354.","journal-title":"Oncol Lett"},{"key":"3906_CR19","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3389\/fonc.2020.01720","volume":"10","author":"K-J Wang","year":"2020","unstructured":"Wang K-J, Wang K-Y, Zhang H-Z, Meng X-Y, Chen J-F, Wang P, et al. Up-regulation of RIP3 alleviates prostate cancer progression by activation of RIP3\/MLKL signaling pathway and induction of necroptosis. Front Oncol. 2020;10:1720.","journal-title":"Front Oncol"},{"key":"3906_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07245-w","volume":"15","author":"K-J Wang","year":"2024","unstructured":"Wang K-J, Ye S-Z, Jia X-L, Wang K-Y, Meng X-Y, Fei X, et al. RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2\u03b1 pathways. Cell Death Dis. 2024;15:844.","journal-title":"Cell Death Dis"},{"key":"3906_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2020.03.004","volume":"478","author":"X Wu","year":"2020","unstructured":"Wu X, Zhou Z, Xu S, Liao C, Chen X, Li B, et al. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett. 2020;478:93\u2013106.","journal-title":"Cancer Lett"},{"key":"3906_CR22","unstructured":"CUT&Tag for efficient epigenomic profiling of small samples and single cells - PubMed. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/31036827\/."},{"key":"3906_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101484","volume":"5","author":"N-M Hoang","year":"2024","unstructured":"Hoang N-M, Liu Y, Bates PD, Heaton AR, Lopez AF, Liu P, et al. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep Med. 2024;5:101484.","journal-title":"Cell Rep Med"},{"key":"3906_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-1433-4_8","volume":"2310","author":"TC Leuthner","year":"2021","unstructured":"Leuthner TC, Hartman JH, Ryde IT, Meyer JN. PCR-based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol. 2021;2310:91\u2013111.","journal-title":"Methods Mol Biol"},{"key":"3906_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-025-02376-8","volume":"10","author":"C Cordier","year":"2025","unstructured":"Cordier C, Haustrate A, Mihalache A, Duval E, Desruelles E, Spriet C, et al. Targeting TRPV6\/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone. Signal Transduct Target Ther. 2025;10:287.","journal-title":"Signal Transduct Target Ther"},{"key":"3906_CR26","first-page":"228","volume":"1865","author":"D Chen","year":"2016","unstructured":"Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta. 2016;1865:228\u201336.","journal-title":"Biochim Biophys Acta"},{"key":"3906_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.tibs.2014.05.002","volume":"39","author":"A Jeltsch","year":"2014","unstructured":"Jeltsch A, Jurkowska RZ. New concepts in DNA methylation. Trends Biochem Sci. 2014;39:310\u20138.","journal-title":"Trends Biochem Sci"},{"key":"3906_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","volume":"21","author":"E Farah","year":"2022","unstructured":"Farah E, Zhang Z, Utturkar SM, Liu J, Ratliff TL, Liu X. Targeting DNMTs to overcome enzalutamide resistance in prostate cancer. Mol Cancer Ther. 2022;21:193\u2013205.","journal-title":"Mol Cancer Ther"},{"key":"3906_CR29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/cancers14082037","volume":"14","author":"A Cazes","year":"2022","unstructured":"Cazes A, Childers BG, Esparza E, Lowy AM. The MST1R\/RON tyrosine kinase in cancer: oncogenic functions and therapeutic strategies. Cancers. 2022;14:2037.","journal-title":"Cancers"},{"key":"3906_CR30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13238-011-1113-3","volume":"2","author":"Q Meng","year":"2011","unstructured":"Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell. 2011;2:889\u201398.","journal-title":"Protein Cell"},{"key":"3906_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02177-w","volume":"8","author":"DB Lipka","year":"2017","unstructured":"Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, N\u00f6llke P, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017;8:2126.","journal-title":"Nat Commun"},{"key":"3906_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13046-020-01711-x","volume":"39","author":"H-P Yao","year":"2020","unstructured":"Yao H-P, Tong X-M, Hudson R, Wang M-H. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res. 2020;39:198.","journal-title":"J Exp Clin Cancer Res"},{"key":"3906_CR33","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/liv.14892","volume":"41","author":"T Weng","year":"2021","unstructured":"Weng T, Yan D, Shi D, Zhu M, Liu Y, Wu Z, et al. The MSP-RON pathway regulates liver fibrosis through transforming growth factor beta-dependent epithelial-mesenchymal transition. Liver Int. 2021;41:1956\u201368.","journal-title":"Liver Int"},{"key":"3906_CR34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41586-024-07812-3","volume":"633","author":"D Bezwada","year":"2024","unstructured":"Bezwada D, Perelli L, Lesner NP, Cai L, Brooks B, Wu Z, et al. Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024;633:923\u201331.","journal-title":"Nature"},{"key":"3906_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrm3877","volume":"15","author":"P Mishra","year":"2014","unstructured":"Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15:634\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3906_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"3906_CR37","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, Marck BT, Plymate S, Vessella R, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913\u201325.","journal-title":"Clin Cancer Res"},{"key":"3906_CR38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575\u201386.","journal-title":"Cancer Cell"},{"key":"3906_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song X-L, Li X-A, Chen M, Guo J, Yang D-H, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"key":"3906_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/onc.2009.331","volume":"29","author":"MN Thobe","year":"2010","unstructured":"Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene. 2010;29:214\u201326.","journal-title":"Oncogene"},{"key":"3906_CR41","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mc.22354","volume":"54","author":"IS Batth","year":"2015","unstructured":"Batth IS, Yun H, Kumar AP. Recepteur d\u2019origine nantais (RON), more than a kinase: role in castrate-resistant prostate cancer. Mol Carcinog. 2015;54:937\u201346.","journal-title":"Mol Carcinog"},{"key":"3906_CR42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1541-7786.MCR-20-0060","volume":"18","author":"C Sullivan","year":"2020","unstructured":"Sullivan C, Brown NE, Vasiliauskas J, Pathrose P, Starnes SL, Waltz SE. Prostate epithelial RON signaling promotes M2 macrophage activation to drive prostate tumor growth and progression. Mol Cancer Res. 2020;18:1244\u201354.","journal-title":"Mol Cancer Res"},{"key":"3906_CR43","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/cdd.2014.77","volume":"21","author":"X-N Wu","year":"2014","unstructured":"Wu X-N, Yang Z-H, Wang X-K, Zhang Y, Wan H, Song Y, et al. Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis. Cell Death Differ. 2014;21:1709\u201320.","journal-title":"Cell Death Differ"},{"key":"3906_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","volume":"54","author":"H Wang","year":"2014","unstructured":"Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54:133\u201346.","journal-title":"Mol Cell"},{"key":"3906_CR45","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1158\/1078-0432.CCR-18-3683","volume":"27","author":"Y Tan","year":"2021","unstructured":"Tan Y, Sementino E, Cheung M, Peri S, Menges CW, Kukuyan A-M, et al. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res. 2021;27:1200\u201313.","journal-title":"Clin Cancer Res"},{"key":"3906_CR46","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.3892\/or.2017.5585","volume":"37","author":"B Yin","year":"2017","unstructured":"Yin B, Liu Z, Wang Y, Wang X, Liu W, Yu P, et al. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells. Oncol Rep. 2017;37:3209\u201318.","journal-title":"Oncol Rep"},{"key":"3906_CR47","first-page":"1","volume":"100","author":"PK Wagh","year":"2008","unstructured":"Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res. 2008;100:1\u201333.","journal-title":"Adv Cancer Res"},{"key":"3906_CR48","doi-asserted-by":"publisher","unstructured":"Guo N, Li MZ, Wang LM, Chen HD, Song SS, Miao ZH, et al. Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. Cancer Biol Therapy. 2022;23. https:\/\/doi.org\/10.1080\/15384047.2021.2024414.","DOI":"10.1080\/15384047.2021.2024414"},{"key":"3906_CR49","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ajpath.2012.08.011","volume":"181","author":"M Puhr","year":"2012","unstructured":"Puhr M, Hoefer J, Sch\u00e4fer G, Erb HHH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181:2188\u2013201.","journal-title":"Am J Pathol"},{"key":"3906_CR50","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/bjc.2014.366","volume":"111","author":"P Massoner","year":"2014","unstructured":"Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c\/205. Br J Cancer. 2014;111:955\u201364.","journal-title":"Br J Cancer"},{"key":"3906_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-66","volume":"10","author":"Q Ma","year":"2011","unstructured":"Ma Q, Guin S, Padhye SS, Zhou Y-Q, Zhang R-W, Wang M-H. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer. 2011;10:66.","journal-title":"Mol Cancer"},{"key":"3906_CR52","doi-asserted-by":"publisher","unstructured":"Kaito S, Aoyama K, Oshima M, Tsuchiya A, Miyota M, Yamashita M, et al. Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization. Nat Commun. 2024;15. https:\/\/doi.org\/10.1038\/s41467-024-50498-4.","DOI":"10.1038\/s41467-024-50498-4"},{"key":"3906_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/187152009787313792","volume":"9","author":"I Dussault","year":"2009","unstructured":"Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem. 2009;9:221\u20139.","journal-title":"Anticancer Agents Med Chem"},{"key":"3906_CR54","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/0008-5472.CAN-12-3583","volume":"74","author":"I Kawada","year":"2014","unstructured":"Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, et al. Dramatic antitumor effects of the dual MET\/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014;74:884\u201395.","journal-title":"Cancer Res"},{"key":"3906_CR55","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1038\/onc.2015.384","volume":"35","author":"J Chakedis","year":"2016","unstructured":"Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, et al. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene. 2016;35:3249\u201359.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03906-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:03:04Z","timestamp":1787608984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03906-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":55,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["3906"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03906-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The proposed studies described in this work have been approved by the Ethical Committee of Ningbo University (Approval: #NBU-2023-102). All written consents were obtained from subjects involving patient information and identity. All animal studies were approved by the Institutional Animal Care & Use Committee (Protocol: #ZJCLA-IACUC-20020111, Hangzhou, China). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}